Stock Research for ALNY


Featured Broker: Ally Invest

Get the due diligence for another stock.


ALNY Stock Chart & Research Data

The ALNY chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALNY chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ALNY Due diligence Resources & Stock Charts

The ALNY stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALNY Detailed Price Forecast - CNN Money CNN View ALNY Detailed Summary - Google Finance
Yahoo View ALNY Detailed Summary - Yahoo! Finance Zacks View ALNY Stock Research & Analysis -

Stock Analysis

TradeIdeas View ALNY Trends & Analysis - Trade-Ideas Barrons View ALNY Major Holders - Barrons
NASDAQ View ALNY Call Transcripts - NASDAQ Seeking View ALNY Breaking News & Analysis - Seeking Alpha
Spotlight View ALNY Annual Report - OTC Report View ALNY OTC Short Report -
TradeKing View ALNY Fundamentals - TradeKing Charts View ALNY SEC Filings - Bar Chart
WSJ View Historical Prices for ALNY - The WSJ Morningstar View Performance/Total Return for ALNY - Morningstar
MarketWatch View the Analyst Estimates for ALNY - MarketWatch CNBC View the Earnings History for ALNY - CNBC
StockMarketWatch View the ALNY Earnings - StockMarketWatch MacroAxis View ALNY Buy or Sell Recommendations - MacroAxis
Bullish View the ALNY Bullish Patterns - American Bulls Short Pains View ALNY Short Pain Metrics -

Social Media Mentions

StockTwits View ALNY Stock Mentions - StockTwits PennyStocks View ALNY Stock Mentions - PennyStockTweets
Twitter View ALNY Stock Mentions - Twitter Invest Hub View ALNY Investment Forum News - Investor Hub
Yahoo View ALNY Stock Mentions - Yahoo! Message Board Seeking Alpha View ALNY Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ALNY - Insider Cow View Insider Transactions for ALNY - Insider Cow
CNBC View ALNY Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALNY - OTC Markets
Yahoo View Insider Transactions for ALNY - Yahoo! Finance NASDAQ View Institutional Holdings for ALNY - NASDAQ

Stock Charts

FinViz View ALNY Stock Insight & Charts - StockCharts View ALNY Investment Charts -
BarChart View ALNY Stock Overview & Charts - BarChart Trading View View ALNY User Generated Charts - Trading View

Latest Financial News for ALNY

See what the IHS Markit Score report has to say about Alnylam Pharmaceuticals Inc.
Posted on Tuesday May 21, 2019

Alnylam Pharmaceuticals Inc NASDAQ/NGS:ALNYView full report here! Summary * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is low for ALNY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold ALNY had net inflows of $3.73 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock
Posted on Monday May 20, 2019

After upgrading Pfizer (NYSE:PFE) to "Outperform" in January and raising its price target on Pfizer stock to $48 in May, one would think there's nothing else Credit Suisse could so to bolster its bullish case, but there is.Source: Kojach Via FlickrFollowing a meeting with the pharmaceutical giant's top brass just a few days ago, on Thursday, Credit Suisse labeled PFE stock a "top pick." It was apparently one heck of a meeting.The specifics prompting the accolade weren't made crystal clear, though Credit Suisse did note that the company's prospects for new products was compelling. Translation: Whatever stoked Credit Suisse's fires is likely to be in the company's late-stage pipeline, which is admittedly more exciting than it has been in a long while.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 7 High-Yield REITs to Buy (Even When the Market Tanks) A Brief Look at PfizerIt's not a story that needs a great deal of retelling. It was an unstoppable powerhouse when it had full patent protection of its erectile dysfunction drug Viagra and faced little competition. But, seeing the writing on the wall, the drugmaker allowed Teva Pharmaceutical Industries (NYSE:TEVA) to begin selling a generic version of the drug in 2017. In the meantime, consumer interest in ED drugs has broadly waned.Pfizer is about to lose ground with blockbuster neuropathic pain drug Lyrica too, which lost patent protection last year, threatening to quickly cut its $5 billion in annual sales in half once generic alternatives become available.It's the same story that plays out over and over within the pharmaceutical industry; these organizations must constantly replenish their portfolios with patent-protected drugs, or risk losing ground.It's something Pfizer hasn't done especially well in recent years.Although Pfizer stock has made reliable if choppy progress since turning around with all other stocks in 2009, revenue growth hasn't been overwhelming. The $53.9 billion in sales generated over the course of the past four reported quarters was not remarkable better than the $52.7 billion figure from a year earlier."Pfizer has been working through a dark period with extensive patent expirations," Credit Suisse analyst Vamil Divan said in late January. "That period is now nearing an end." Solid PipelineWhat Pfizer told Credit Suisse at the meeting remains veiled, though when Divan upgraded Pfizer stock early this year he explicitly noted opportunities for several cancer and autoimmune disease drugs along with vaccinations.Two of the drugs Divan had in mind are Vyndaqel and Vyndamax (though they're actually different doses of the same molecule), which combats the buildup for amyloid in the heart.Alnylam Pharmaceuticals (NASDAQ:ALNY) and Ionis Pharmaceuticals (NASDAQ:IONS) already make similar rival drugs, but their versions are considerably more expensive. Divan foresees peak sales of $2 billion for Vyndaqel, but is willing to entertain a number "significantly larger than that if Pfizer is able to commercialize it successfully."Pfizer has also partnered with Eli Lilly (NYSE:LLY) on the development of a non-opioid arthritis treatment called tanezumab, another one of the 15 game-changing drugs Pfizer believes could be brought to the market within the next five years.Some analysts are looking for modest peak sales of around $500 million, although Cantor Fitzgerald analyst Louise Chen thinks tanezumab could prove to a multi-billion dollar opportunity to replace a significant piece of the existing opioid market.In the meantime, Pfizer aims to widen the uses of already-marketable drugs like Ibrance, Eliquis, and Xeljanz.Ibrance has already become something of a wonder drug. Already approved as a therapy for multiple forms of breast cancer and generating revenue of $4.1 billion last year, expanded labeling could translate into peak annualized revenue of $8 billion before the treatment hits its ceiling.Eliquis (or Apixaban) for blood clots, co-marketed with Bristol-Myers Squibb (NYSE:BMY), and arthritis/ulcerative colitis therapy Xeljanz generated nearly $3.5 billion and more than $1.7 billion worth of revenue for Pfizer last year, respectively, yet both are also in trials for new uses after having proven they're safe and effective.All told, Pfizer's got 23 phase 3 trials underway right now. All of them look promising; most of them appear to have blockbuster potential. Looking Ahead for Pfizer StockIt was self-serving to be sure when CEO Albert Bourla proclaimed in January that Pfizer is sitting on its "greatest pipeline ever."But that doesn't mean he's wrong.Granted, the deterioration of Pfizer stock since December's peak (PFE stock been performing completely contrary to the market for months) says investors don't exactly believe Bourla. The crowd has understandably become a "show me first" mob, willing to wait on the sidelines for proof that the pipeline can do all the company suggests it can do.Credit Suisse's Divan may have the right idea though. The time to step into a great prospect is when its stock is down because the majority of investors aren't convinced and analysts are collectively lukewarm because they're unable to see more than a few months down the road.That's certainly Pfizer stock right now.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about James at his site,, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 4 Top American Penny Pot Stocks (Buy Before June 21) * 7 High-Yield REITs to Buy (Even When the Market Tanks) * 5 Great Blue-Chip Stocks to Buy Today * 7 Tech Stocks to Buy That Are Also Perfect for Retirement Compare Brokers The post Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock appeared first on InvestorPlace.

Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019
Posted on Thursday May 09, 2019

Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 am PT (12:20 pm ET) at the Encore Hotel in Las Vegas, Nevada.

Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Posted on Wednesday May 08, 2019

Sector ETF report for PBE

Stock Market & Investing Books

Enter a stock symbol to view the stock details.